Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Zogenix (ZGNX) jumps 36% as FDA snubs own panel to approve stronger hydrocodone

Canadian Press, The Canadian Press
0 Comments| October 25, 2013


WASHINGTON _ The Food and Drug Administration has approved a stronger, single-ingredient version of the painkiller hydrocodone, the widely-abused prescription medicine for chronic pain.
 
The agency said it approved the Zogenix (NASDAQ:ZGNX, Stock Forum) pill Zohydro for patients with pain that requires, daily, around-the-clock treatment that cannot be addressed with other drugs.
 
The approval comes as a surprise since the agency's own panel of outside advisers gave an overwhelmingly negative review of the product last year. The FDA's panel of pain specialists voted 11-2 against approving the drug last December, questioning the need for a new form of one of most widely-abused prescription painkillers in U.S.
 
The FDA announcement also comes just a day after the agency said it would recommend stronger controls on combination drugs containing hydrocodone, such as Vicodin.

Tags: DRUG MANUFACTURERS - MAJOR ETF

Rate this article
0 stars
v
Usefulness

Clarity

Credibility

Comments

No comments yet. Be first to comment!

Leave a Message

You must be logged in to access this feature.